Pancreaticoduodenectomy with combined hepatic artery and portal vein resection after laparoscopic division of pancreaticosplenic ligament due to FOLFIRINOX-induced hepatic toxicity related secondary hypersplenism by 강창무 et al.
Ann Hepatobiliary Pancreat Surg 2021;25:307-312
https://doi.org/10.14701/ahbps.2021.25.2.307 Case Report
Pancreaticoduodenectomy with combined hepatic artery and 
portal vein resection after laparoscopic division of 
pancreaticosplenic ligament due to FOLFIRINOX-induced 
hepatic toxicity related secondary hypersplenism
Ji Su Kim1,4, Jeong Youp Park2,4, Munseok Choi5, Dong Jin Joo3, 
Ho Kyoung Hwang1,4, Woo Jung Lee1,4, and Chang Moo Kang1,4
1Division of Hepatobiliary and Pancreatic Surgery, 2Division of Gastroenterology, Department of Internal Medicine, 
3Division of Transplantation, Department of Surgery, Yonsei University College of Medicine, 
4Pancreatobiliary Cancer Center, Yonsei Cancer Center, Severance Hospital, Seoul, 
5Department of Surgery, Yongin Severance, Yongin, Korea
Pancreatic cancer is one of the dismal malignant disease in gastrointestinal tract. However, since the recent literature 
reporting median survival of FOLFIRINOX (leucovorin clcium, fluorouracil, irinotecan hydrochloride, oxaliplatin) chemo-
therapy was more than 12 months in metastatic pancreatic cancer was published, the positive attitude toward the 
treatment of the advanced pancreatic cancer is gradually expanded among the medical and surgical oncologists. Due 
to multiple combination of potent chemotherapeutic agents, potential adverse side effects should be concerned when 
considering FOLFIRINOX. Herein, we report a 55-year old male patient with locally advanced pancreatic cancer who 
successfully underwent curative resection following by laparoscopic division of pancreaticosplenic ligament due to 
long-term preoperative use of FOLFIRINOX related hepatic toxicity associated with secondary hypersplenism. The pres-
ent case suggests the extended radical PD with combined major vascular resection following laparoscopic division 
of pancreaticosplenic ligament containing splenic artery and vein can improve the safety of curative resection and may 
expand the potential indication of pancreatic cancer in well-selected long-term use of preoperative FOLFIRINOX in-
duced hepatic toxicity associated with secondary hypersplenism. (Ann Hepatobiliary Pancreat Surg 2021;25:307-312)
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INTRODUCTION
Is FOLFIRINOX (leucovorin calcium, fluorouracil, iri-
notecan hydrochloride, oxaliplatin) light to the pancreatic 
cancer treatment? It is known that pancreatic cancer is one 
of the dismal malignant disease in gastrointestinal tract. 
However, since the recent literature reporting median sur-
vival of FOLFIRINOX chemotherapy was more than 12 
months in metastatic pancreatic cancer was published,1,2 
the positive attitude toward the treatment of the advanced 
pancreatic cancer is gradually expanded among the medi-
cal and surgical oncologists. It was also reported that the 
long-term survival outcome of FOLFIRINOX was found 
to be extremely superior to conventional gemcitabine in 
postoperative adjuvant setting.3
Due to multiple combination of potent chemotherapeutic 
agents, potential adverse side effects should be concerned 
when considering FOLFIRINOX in clinical practice.4 In 
addition, with advance of surgical techniques for mar-
gin-negative pancreatectomy and under the rationales to 
support several oncologic benefits of neo-adjuvant chemo-
therapy in pancreatic cancer, conversion surgery following 
preoperative chemotherapy is actively considered in lo-
cally advanced pancreatic cancer.5
In this case, we report successful pancreaticoduodenec-
tomy (PD) with combined vascular resection following 
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Fig. 1. Preoperative CT scan. Invasion of pancreatic head cancer around SMV-SV-PV confluence and CHA was noted at the 
time of diagnosis (A). Soft tissue infiltration was still noted without progression after neo-adjuvant chemotherapy (B). White 
Dotted circle indicates tumor area and thick long white arrow indicates cancer infiltrating around common hepatic artery (B, 
C). Note atrophic change of distal part of the pancreas makes enough space between tip of the pancreas and splenic hilum 
(yellow arrow). Potential division line of pancreaticosplenic ligament was noted (red dotted line, C). CT, computed tomography; 
SMV, superior mesenteric vein; SV, splenic vein; PV, portal vein; CHA, common hepatic artery.
Fig. 2. Liver volume at initial CT (A), preoperative (B) and the postoperative (POD#7) CT (C). (A=1488.61 cm3, B=1077.97 
cm3, C=1294.85 cm3) Note liver atrophy (yellow arrow) after long-term neoadjuvant chemotherapy with relatively enlarge spleen. 
CT, computed tomography; POD, postoperative days.
laparoscopic division of pancreaticosplenic ligament in 




A 55 years old male initially visited the hospital with 
jaundice. He doesn’t have any other clinical disease and 
past history. Computed tomography(CT) imaging identi-
fied a tumor invaded more than 180 degrees in Common 
hepatic artery (CHA), Gastroduodenal artery (GDA), Portal 
vein (PV) (Fig. 1A). He diagnosed locally advanced pan-
creatic head cancer with major vascular invasion. After 
endoscopic retrograde biliary drainage (ERBD), he started 
neo-adjuvant chemotherapy with FOLFIRINOX full dose 
(147.9 mg/m2 of oxaliplatin, 348 mg/m2 of leucovorin, 
313.2 mg/m2 of irinotecan, and a total of 2784 mg/m2 of 
fluorouracil) in February 2017. When he received 11th 
FOLFIRINOX, he developed neutropenia and thrombocy-
topenia, requiring dose reduction to 75%.
After finished 12th FOLFIRINOX, the tumor was sta-
ble and responded to neo-adjuvant chemotherapy. Even 
though still invaded CHA and PV, tumor size was de-
creased to 2 cm from 3 cm. It was still in unresectable 
status, so he was decided to take concurrent chemo-radia-
tion therapy (CCRT) with Xeloda in September 2017. 
During CCRT, his neutropenia and thrombocytopenia got 
worse. In December 2017, he started chemotherapy with 
13th FOLFIRINOX, only 25% dose used. From 15th 
FOLFIRINOX, 50% dose was used. In March 2019, after 
finishing all 32th FOLFIRINOX, follow up CT scan 
Ji Su Kim, et al. To enhance the safe radical pancreatectomy for locally advanced pancreatic cancer  309
Fig. 3. Chronological change of 
blood platelet count according 
to pancreatic cancer treatment. 
FOLFIRINOX, leucovorin cal-
cium, fluorouracil, irinotecan hy-
drochloride, oxaliplatin; CCRT, 
concurrent chemoradiation the-
rapy.
showed no interval change of primary pancreatic cancer, 
with CHA, and PV invasion (Fig. 1B). Liver atrophy 
worsened and total liver volume decreased to 1077.97 cm3 
from 1488.61 cm3 (Fig. 2A, B). Thrombocytopenia (79,000 
ul) was still noted (Fig. 3), which was thought to be due 
to long-term use of FOLFIRINOX-induced liver toxicity 
related portal hypertension with secondary hypersplenism.
Operation
The Pylorus preserving pancreaticoduodenectomy (PPPD) 
with PV, CHA segmental resection was planned for this 
patient. Initially, diagnostic laparoscopy was performed to 
check occult metastasis. No systemic metastasis or peri-
toneal seeding was noted. In order to compensate potential 
thrombocytopenia, pancreaticosplenic ligament containing 
splenic artery and vein resected near the spleen hilum us-
ing an Endo-GIA stapler (Figs. 1C and 4A, B). Then lapa-
rotomy was performed to proceed PPPD with combined 
vascular resections. Superior mesenteric vein (SMV)–PV 
end to end anastomosis, and CHA–Proper hepatic artery 
(PHA) end to end anastomosis were simultaneously done 
(Fig. 4C, D).
Postoperative outcome and recovery
The total operation duration was 641 minutes and the 
estimated intraoperative blood loss was 1850 cc. He re-
ceived postoperative treatment in an intensive care unit 
for intensive care and surveillance after surgery. The two 
Pack of Red Blood Cells (RBC) and Fresh Frozen Plasmas 
(FFP) were transfused immediately. At the postoperative 
3rd days, transferred to the general ward after his vital 
signs were stable. He recovered routinely without any spe-
cific problem except for wound seroma. On 7th post-
operative days, there were no specific finding in abdomen 
on routine CT. Liver recovered volume from 1077.97 cm3 
to 1294.86 cm3 (Fig. 2B, C). After improved wound, He 
discharged hospital at the 15 days after surgery. At the 
discharge day, blood platelet count was found to be 
334,000 ul (Fig. 3).
Pathological examination
The final histopathological result was reported as a duc-
tal adenocarcinoma of moderate differentiation after che-
motherapy. All resection margins were reported as free 
from carcinoma. There was no metastasis to the 8 re-
trieved lymph nodes. He is on follow-up for 7 months 
without adjuvant chemotherapy.
DISCUSSION
In this patient, the patient was initially regarded as lo-
cally advanced pancreatic cancer due to pancreatic head 
cancer invading to PV and CHA. Subsequent long-term 
use of FOLFIRINOX-based chemotherapy could prevent 
cancer progressing. However, liver cirrhosis-like liver 
contour with small ascites and secondary thrombocytope-
nia due to hypersplenism need to be considered in plan-
ning surgical tactics in treating this patient. The surgical 
procedure needed to be determined, considering curative 
resection, patient’s safety and long-term scenario of po-
tentially worsening liver function after pancreatectomy.
FOLFIRINOX is frequently used in the neo-adjuvant 
setting to downsize borderline resectable or locally ad-
vanced pancreatic cancer patients because it improves the 
overall survival rate and slows progression of the cancer.6,7 
However, there are strong correlation between oxaliplatin 
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Fig. 4. Operative finding: Laparo-
scopic division of pancreatico-
splenic ligament containing both 
splenic artery and vein near spleen 
hilum using Endo-GIA stapler 
(stapler line-white long arrow). 
(A, B) Tumor invaded CHA 
and SMV (C), PHA-CHA (yellow 
long arrow) and PV-SMV “(white
short arrow)”, end to end ana-
stomosis (D). Endo-GIA, endo-
scopic gastrointestinal anastomo-
sis; S, Stomach; Sp, spleen; PT, 
pancreas tail; C, colon; BD, bile 
duct; PHA, proper hepatic artery; 
CHA, common hepatic artery; 
P, remnant pancreas; SV, splenic 
vein; T, tumor; SMA, superior 
mesenteric artery; SMV, superior 
mesenteric vein.
and sinusoidal obstruction syndrome,8,9 which is well 
known one of the causes of portal hypertension. In this 
patients, the patient’s initial liver contour and blood plate-
let count were normal. After long-term 32th cycle of 
FOLFIRINOX, sustained thrombocytopenia and atrophied 
liver shown on preoperative CT scan were suggesting re-
peated cycles of FOLFORINOX might result in sinusoidal 
obstruction syndrome and secondary hypersplenism due to 
subsequent portal hypertension. 
Considering potential adverse impact of preoperative 
long-term use of FOLFIRINOX, PD with combined seg-
mental resection of CHA and PV after laparoscopic divi-
sion of both splenic artery and vein near the splenic hilum 
was planned for this patients. This strategy is thought to 
be able to preserve the spleen, resolve the secondary 
thrombocytopenia and temporally prevent future potential 
perigastric varix by disconnecting all venous communica-
tion from portal venous system (During surgical procedure 
of PD, right gastric vein, right gastroepiploric vein, left 
gastric vein, and distal splenic vein were all divided), ex-
pecting improvement of patient’ liver function and safety 
of the extended surgical procedure, as well. As result, it 
was observed that preoperative thrombocytopenia, liver 
volume, and liver function were all improved post-
operatively in the present case.
There are several studies showing combined splenec-
tomy could improve liver function in patients with liver 
cirrhosis.10-12 However, spleen is one of the largest im-
munologic organ in human body, and splenectomy can be 
associated with infection-related postoperative complica-
tions13 and severe sepsis.14 In addition, cancer patient, po-
tential role of spleen as anticancer effect is concerned. 
Especially, Hwang, et al.15 recently observed multiple per-
itoneal seeding nodules of recurrent pancreatic cancer in 
splenectomized mouse (25%), suggesting decreased activ-
ity of NK cell after splenectomy as possible mechanism 
of multiple peritoneal seeding in splenectomy group. 
Therefore, instead of concomitant splenectomy, the pres-
ent approach, just division of both splenic artery and vein 
near the splenic hilum, is thought to be the best option 
when planning for curative intent PD in pancreatic cancer 
patients with portal hypertension with secondary hyper-
splenism. 
Initial laparoscopic approach was considered in this pa-
tient; First, unexpected detection of peritoneal seeding and 
hepatic metastasis is not uncommon in patients with ad-
vanced pancreatic cancer.16,17 Second, it is thought that 
laparoscopic division of pancreaticosplenic ligament to 
control both splenic artery and vein is one of the common 
procedures for laparoscopic splenic vessels-sacrificing spleen- 
preserving distal pancreatectomy, so called Warshaw’s 
procedure.18,19 Lastly, obtaining operative field and surgi-
cal manipulation around splenic hilum is thought to be 
much easier under the laparoscopic view than open ap-
proach.
PD with combined hepatic artery and PV resection fol-
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lowing neo-adjuvant chemotherapy is currently feasible 
surgical procedure in well-selected borderline and locally 
advanced pancreatic cancer.20-22 Not to mention of ad-
vance in surgical technique for curative resection and 
postoperative management, introduction of potent chemo-
therapeutic agents and improving patients general con-
dition will increase long-term oncologic outcome of re-
sected pancreatic cancer in near future.
The present case suggests the extended radical PD with 
combined major vascular resection following laparoscopic 
division of pancreaticosplenic ligament containing splenic 
artery and vein can improve the safety of curative re-
section and may expand the potential indication of pancre-
atic cancer in well-selected long-term use of preoperative 
FOLFIRINOX induced hepatic toxicity associated with 
secondary hypersplenism. The more active application of 
FOLFIRINOX in locally advanced pancreatic cancer, the 
more cases like the present report are highly expected to 
be encountered in clinical practice. The long-term effect 
of this surgical approach is still questioned. Further expe-
riences are mandatory.
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